The question which policy makers really need answering is 'How well do the new initiatives aimed at enabling a knowledge-based health (KBH) service work?'. It would be scarcely credible for a movement whose rationale is the need for scientific evidence in practice, not to supply its own proof. But that is very difficult. The KBH service or evidence-based healthcare (EBH) movement is a very new and complex intervention; and the methods for evaluating complex interventions are very raw. As a preliminary, however, we can provide some facts on the background to EBH, its major components and early indications as to its effect. In passing, we note that some prefer to speak of healthcare becoming more knowledge based rather than evidence based. The distinction is made to reflect the fact that healthcare decisions (whether about a patient or a population) need to be based on research-based evidence about the consequences of treatments augmented by the intelligent use of wider information on, for example, finance, patient flows and healthcare politics.
INTRODUCTION
The question which policy makers really need answering is 'How well do the new initiatives aimed at enabling a knowledge-based health (KBH) service work?'. It would be scarcely credible for a movement whose rationale is the need for scientific evidence in practice, not to supply its own proof. But that is very difficult. The KBH service or evidence-based healthcare (EBH) movement is a very new and complex intervention; and the methods for evaluating complex interventions are very raw. As a preliminary, however, we can provide some facts on the background to EBH, its major components and early indications as to its effect. In passing, we note that some prefer to speak of healthcare becoming more knowledge based rather than evidence based. The distinction is made to reflect the fact that healthcare decisions (whether about a patient or a population) need to be based on research-based evidence about the consequences of treatments augmented by the intelligent use of wider information on, for example, finance, patient flows and healthcare politics.
BACKGROUND TO EBH
There has been a recent explosion of journals, conferences, books and even research expenditure on EBH",2. The latter includes much of the National Health Service (NHS)
Research and Development Strategy launched in 1991 3.
This notably includes the rolling Health Technology Assessment (HTA) Programme, and the 1995-1996 programme of research on Methods to Promote the Implementation of Research Findings in the NHS4,5. The HTA Programme funds some 40-50 systematic reviews and trials per year and the implementation programme has funded research on 20 dissemination themes. The findings of the latter should shed interesting light on the effectiveness of dissemination of the evidence base. Although the burst of activity amounts to an effectiveness Correspondence to: Professor Andrew Stevens revolution1 there are three strong antecedent traditions in EBH.
First, EBM has roots in clinical epidemiology and owes much to Cochrane's (1972) critique of 'effectiveness and efficiency'6. It has been further stimulated by the literature on unexplained geographical variations7'8, and other pointers to the gap between evidence and care. Antman et al.'s9 demonstration of a disturbing lag between the availability of evidence on clinical effectiveness and its recognition in definitive textbooks, let alone its use in clinical practice9 is just one example. By comparing the evidence and the textbook recommendations for treatments in myocardial infarction, Antman and colleagues demonstrated that the benefits of, for example, thrombolytic therapy could have been clear more than a decade before experts were recommending it.
Second, health economics as a distinct academic speciality has grown steadily from the mid-1970s to the present in response to both cost pressures and the search for means to inform trade-offs between alternative calls on healthcare expenditurelU. The recognition that all investments in healthcare have opportunity costs (benefits which would have been gained from the investment's best alternatives) has greatly widened the appeal and influence of health economics.
Third, health technology assessment is the term used for policy-driven evaluation and has its origins in the USA where the Office of Technology Assessment was set up in 197211. There are now parallel organizations in many countries such as Sweden's SBU (the Swedish Council on Technology Assessment in Health Care) and Britain's NCCHTA (National Co-ordinating Centre for HTA) which underscore the close relationship, at least in intent, between EBH and policy and practice.
KBH SERVICES IN BRITAIN
In the UK, there is a fast-growing number of initiatives, each with its own acronym, concerned with KBH services. Examples include not just the nationally funded NCCHTA at Southampton, the NHS Centre for Reviews and Dissemination (CRD) at York, and the UK KBH is a major undertaking. It is major because of a numbers problem, a customer problem, and a barrier to change problem. All of these mean that establishing a knowledge base for healthcare is not a single task but an array of tasks with different time scales, customers and functions. Those who advocate simplification either because of an administrative concern for neatness, or because they are evangelists for one true path, are at best too impatient and at worst unhelpful to the needs of the service.
The numbers problem is about the scale of healthcare. There are upwards of 100 new drugs or distinct new medications licensed per year. About 1000 potential new research priorities are identified for the HTA Programme each year (of which 40 or so are funded). There are at least 10 000 distinct disease groups (there are 2000 three-digit ICD codes) and easily ten times as many distinct interventions. It is startling that there are 16 000 active medical journals (of which 4000 are on Medline). In short, there is a lot of activity for which an evidence base is needed.
The customer problem concerns the variety of different audiences all with their different time constraints, distractions and prejudices at whom the evidence base is directed. A list of categories might include hospital specialists, general practitioners, general managers, public health physicians, nurses, professions allied to medicine and health services researchers. Each group has different needs in terms of skills, density of evidence, and timing of access to evidence. In particular, some require locally sensitive information open to local debate and participation.
The barrier problem concerns the difficulties of engaging the audience for KBH. Commissioners of healthcare, for example, are legitimately distracted by other influences on their decisions, particularly top-down priorities, professional advice, and the involvement of local people12. Also clinicians (see Grimshaw and Thomson this issue, p. 20) are subject to a number of barriers to change.
Oxman13 identifies these as including: (i) time constraints people are busy; (ii) information managementthe right information needs to be at hand at the right time; (iii) financial disincentives the evidence-based approach may be costly, and as a general rule, change is costly; (iv) perceptions of liability changing away from conventional practice may make people feel exposed to litigation; (v) patient expectations patients may demand what they are used to, or may demand treatments subject to media hype; (vi) advocacy-some practitioners are enthusiastic avocates of particular interventions, for whatever reason; and (vii) sense of competence it takes time to feel comfortable with innovation which may require a period of learning before one is happy with it13.
These problems, numbers, people and barriers, and hence the wide array of tasks in KBH, both concerning production and dissemination of knowledge, explains the array of players and initiatives which exist under the barrier of KBH. A means of classifying these players and initiatives is set out in Table 1 .
FUNDING BODIES
First, whatever the activity, it needs funding. Funding bodies in the UK include the NHS Research and Development Programme, particularly the centrally commissioned programmes which have the unusual feature of being 'needs' (need for research) led. Needs-led research is research based on an assessment of the most important evidence gaps in the healthcare knowledge base. It is distinct from traditional research funding of suggestions provided by researchers which usually reflect their personal research interests. The effort involved in defining research needs partly explains why funding bodies are distinct from coordinating and networking bodies.
COORDINATING AND NETWORKING BODIES
The HTA Programme, for example, requires elaborate process of priority setting to try to ensure that the 40 funded research priorities have more merit than the 1000 or so which cannot be funded each year. Identifying, prioritizing and also commissioning, monitoring and disseminating the output are substantial tasks undertaken by the NCCHTA. The UK Cochrane Centre networks with the international Cochrane collaboration aimed at monitoring systematic reviews of randomized control trials. It also maintains the Cochrane Library of databases of reviews (CDSR), trials (CCTC) and methodological reports (CRMD). The NHS Centre for Reviews and Dissemination prepares systematic reviews, disseminates the Effective Healthcare Bulletins and Effectiveness Matters and maintains databases of review abstracts (DARE) and economic evaluation abstracts (NHS Economic Evaluation Database).
RESEARCH EVIDENCE
The research evidence that comprises EBH can be seen as occurring at three distances from the end user. Distance one, primary research, (well-designed randomized trials and observational studies) is the traditional meat of evidence. However, at the heart of the EBM movement, is the logic of the need for systematic reviews, i.e. distance two. Systematic reviews draw together all the reliable evidence relevant to a particular intervention and are defined as 'reviews in which the evidence (usually from randomized controlled trials) on a topic has been systematically identified, appraised and summarized according to predetermined criteria. Such reviews can be systematic (taking steps to avoid bias) without using statistical synthesis (meta analysis) to reduce inprecision [Definition from Cochrane Library (1996 Issue 3) Glossary, London: BMJ]. The case for systematic reviews has been made robustly and needs no repeating14'15. The Cochrane databases are databases of such reviews. Paradoxically, perhaps, the increasing rigour of evidence synthesis within systematic reviews has contributed to clarifying the need for distance three: other structured reviews. Structured reviews are necessary because end users, particularly commissioners and planners of healthcare, frequently require a reliable perspective on a and often on a shorter time scale. 'Going wider' means covering more than one intervention (e.g. an entire disease as in the Health Care Needs Assessment series) 16 7, or covering additional information such as epidemiology, current services, or (typically) costs. Being required on a short time scale is often a case of a review being required when the level of evidence is still limited to a single phase III drug trial and a few case series. Assessment can be urgently required given the rate of diffusion of new technologies (often drugs such as beta interferon for multiple sclerosis or donepezil for Alzheimer's disease) into the health service. This latter function is filled by a number of regional strategic initiatives, including DEC reports, from the South and West and, latterly, Trent regions. Although many of these reports follow all the rules of strict systematic reviews, they often have to be based on a limited literature and an element of modelling to provide useful conclusions (see section on DEC reports below).
PUBLICATION AND DISSEMINATION MEDIA
The mere existence of an evidence base whether at distance one, two or three implies the need for publication and dissemination media. The NCCHTA's dissemination strategy for the HTA Programme well illustrates some of the issues around dissemination, particularly the distinction between proactive ('current awareness') and routine ('lookup') publication made by Haynes et al. 18 . The difference is that current awareness sources such as press releases, conferences and marketing initiatives generally seek to capture the attention of audience. However, they cannot guarantee to do so except at a time when the potential audience is ready, available or interested in the message. It needs to be used sparingly, for a few major issues. In the case of the HTA Programme, the case against prostate cancer screening made by two separate systematic reviews (and a number from abroad)19-21 was argued to be such an issue. By contrast 'look-up' dissemination methods are aimed at ensuring evidence is easily available to those who are actively seeking it. Peer-reviewed journals included on Medline, are the obvious example, but recognized monograph series (the HTA Programme has one) and web-sites would be included too. Finding such information is the bread and butter activity of qualified healthcare librarians.
Medline is just one of a number of on-line (and CD Rom) databases in medical research. Others include EMBase, HealthSTAR and specialty-specific databases such as CANCERLIT and PSYCHLIT. These, and many other databases, can be thought of as a technological step forward from browsing journals and hand searching, although full healthcare topic which goes wider than a systematic review 28 Su pp ement No 35 Volume 91 1 9 9 8 systematic reviews require both electronic and hand 1 998 searches. However, because most electronic databases are not specifically focused on EBH they lead to both sensitivity problems (i.e. a failure to find all relevant articles) and specificity problems (i.e. retrieval of much irrelevant material). We have therefore moved on to a new technological phase of such evidence-based compendia as Best Evidence and the Cochrane Library18. The national research register (NRR) which seeks to provide an electronic list of NHS and Medical Research Council research, funded and underway, but not yet complete might be considered under this heading although it goes beyond effectiveness research. Such advances, however, do not necessarily cover the needs of healthcare commissioners and policy makers. A similar sensitivityspecificity problem exists in seeking information for healthcare policy where both research evidence and key policy documents may be required. The GEARS (getting easier access to reviews) database produced in Southampton University seeks to solve this problem. It combines a download of Medline reviews and editorials from key journals with listings of key 'grey' literature documents such as NHS Executive Commended Guidelines, Royal College reports, South and West Development and Evaluation Committee reports (DEC) and the like. It is specifically aimed at purchases and policy makers.
INTERPRETING THE EVIDENCE
Another problem for purchasers and policy makers and, indeed, clinicians is interpreting and judging the evidence. One way in which this can be achieved is by a wide take-up of critical appraisal skills. The hierarchy of research designs (from multiple randomized controlled trials suitably metaanalysed at the top, to consensus lacking a research base at the bottom) and for critical appraisal both of reviews and policy research22 are part of the conventional wisdom of EBH. But full familiarity with critical appraisal skills take some training and alternative solutions are sometimes required. One such is the so-called Aggressive Research Intelligence Facility in the West Midlands. It responds to requests for information (usually from health authorities) by both a search from good systematic reviews and a critical appraisal report on their quality and value. Furthermore, best evidence is not just a database compendium but also plays a vital evidence interpretation role.
THE SOUTH AND WEST DEVELOPMENT AND EVALUATION SYSTEM
A particular initiative which illustrates many of the characteristics of KBH is the South and West (of England) Development and Evaluation Service23'24. Essentially the service provides rapid high quality structured reviews to healthcare purchasers. It has been a notable success with a production run of some 140 reviews since 1993. Each review is produced to a rigorous structure, is peer reviewed and produced within 3 to 6 months of a topic being identified. The system has parallels in other parts of the UK, notably Trent and Scotland, and further systems are planned elsewhere. Its critical features are: there is a quadripartite involvement of health authorities (and sometimes providers) of healthcare who request a report; a research team who produce it; a committee (the Development and Evaluation Committee) who arbitrate, produce a judgement and take responsibility for the outcome and regional research and development who fund the process and publish its findings (see Figure 1 ). The involvement of health authorities at the outset guarantees a real need for timely evidence. Notably, the need for evidence on, for example, beta interferon in multiple sclerosis and donepezil in dementia, were identified and responded to much more rapidly by this mechanism than by 'top-down' initiatives. The stable research team working to a fixed protocol, following the roles of systematic review production guarantees a reliable result25. The result is the more valued for an additional, all important, modelling of cost utility required for each report. The Committee acts to peer review reports (in addition to peer review prior to submission to the Committee), to add clinical insights in to the context of each evaluated intervention, to recommend a conclusion, and to take responsibility for subsequent dialogue.
The basis of the Committee's conclusions which can be 'strongly recommended, recommended, borderline, not recommended, or not proven' is crucial. These conclusions are based on two central features of EBH care: (i) the magnitude of the effect of the intervention; and (ii) the quality of the evidence. The magnitude of the effect is here turned into a cost-magnitude ratio using cost per-quality adjusted life year (QALY). The quality of the evidence is based on the now standard US Task Force on Preventive Services reports which rates randomized controls highest, and consensus without evidence lowest26. The relationship between these dimensions and the Development and Evaluation Committee's recommendations is set out in Table 2 . The use of QALYs to describe magnitude of effect raises technical issues about QALY estimation. But the general principle of benefit being a function of length and quality of life is widely accepted. The scale in Table 2 has been discussed elsewhere23'24.
CONCLUSION
The South and West Development and Evaluation system, together with the other elements of a growing system set out in Table 1 are a heartening constellation of initiatives to those concerned with KBH. Doubtless there will be a further phase of new initiative development, followed by increasing synchronization, as different bodies learn from each other and coordinate their efforts. To some extent that is happening internationally through INAHTA (International network of agencies for health technology assessment), and in the UK through an informal network of regional initiatives. But it would be a mistake for rationalization to be pushed at the expense of innovation and development. Although the tools for generating the information required are becoming increasingly well established, the number of topics for review is all but endless. The means of successful communication and implementation of the results are barely researched. The excitement phase of KBH will be with us for a while.
